Cumberland Pharmaceuticals Inc.

Good afternoon and welcome to the Cumberland Pharmaceuticals first quarter 2025 financial report and company update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I would now like to turn the call over to Molly Agus, Account Supervisor at the Dalton Agency, who handles Cumberland's communications. Molly, please proceed.

Hello everyone and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its first quarter financial results. The release also provided an operational update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. Management will share an overview of those financial results during today's call. They'll also provide an overall company update, including a discussion of Cumberland's brands, pipeline, and partners. Participating in today's call are AJ Kazemi, Cumberland's Chief Executive Officer, along with Todd Anthony, Vice President, Organizational Development, and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements, as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events. It may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions, and others that are beyond the company's control. Those issues are described under the caption risk factors. in Cumberland's Form 10-K and any additional updates filed with SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements. whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product websites, and you can find links to those sites on the corporate website at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to gap measures can be found in the financial tables of the earnings release, which I noted was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we'll be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call, if you prefer. And with that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Cazzini.

Thank you, Molly, and good afternoon, everyone. We appreciate your joining us today. As Molly mentioned during the call, we'll provide a review of our financial results for the first quarter of 2025, and we'll also discuss key developments that occurred during the period. So let's get started. We've enjoyed a strong start to the year. There were a series of positive developments during the first quarter, which we'll discuss today that bolster our optimistic view about the company's future. Our portfolio of FDA approved brands delivered combined revenues of $11.7 million during the first quarter, a 38% increase over the prior year period. Our balance sheet also improved with 70 million in total assets, including $50 million in cash, along with a significant decrease in debt, resulting in total liabilities of $42 million and shareholders' equity of $51 million. This significant growth was fueled by a $3 million milestone payment associated with the approval of our Vibative brand in China. As a result, we delivered a net profit of $1.26 million for the quarter and adjusted earnings of $2.4 million and cash flow from operations of $3.9 million. In February, We announced positive top-line results from the Phase II study evaluating our ifitroban product candidate in patients with Duchenne muscular dystrophy, or DMD. We believe this marks a breakthrough for these patients, as it's the first successful Phase II study specifically targeting the cardiac complications of their condition. The study results were selected for a late-breaking presentation in March. at the Muscular Dystrophy Association's clinical and scientific conference. That platform allowed us to share our promising results with the global DMD community, which included leading researchers, clinicians, and patient advocates who are all working tirelessly to improve outcomes for those affected by this devastating disease. Next step for our DMD program include further data analysis, and completion of a full study report in preparation for an end of phase two meeting with the FDA to determine the requirements for the product's approval. Meanwhile, we were delighted to learn that our potent antibiotic, Vibative, received approval from the regulatory authorities in China. That milestone provides us with access to the world's second largest pharmaceutical market for the product And we look forward to the launch of Vibative, expected later this year. So with that overview, I'd now like to turn to Todd Anthony, Cumberland's Vice President, Organizational Development, to further discuss both our brands and our organization. Todd?